JPWO2020132474A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020132474A5 JPWO2020132474A5 JP2021535939A JP2021535939A JPWO2020132474A5 JP WO2020132474 A5 JPWO2020132474 A5 JP WO2020132474A5 JP 2021535939 A JP2021535939 A JP 2021535939A JP 2021535939 A JP2021535939 A JP 2021535939A JP WO2020132474 A5 JPWO2020132474 A5 JP WO2020132474A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- disorders
- psychosis
- pharmaceutically acceptable
- salt form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 208000035475 disorder Diseases 0.000 claims description 26
- 150000003839 salts Chemical group 0.000 claims description 18
- 208000028017 Psychotic disease Diseases 0.000 claims description 14
- 208000011117 substance-related disease Diseases 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 11
- 206010013663 drug dependence Diseases 0.000 claims description 10
- 201000000980 schizophrenia Diseases 0.000 claims description 10
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 8
- 206010012289 Dementia Diseases 0.000 claims description 8
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 8
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 8
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 8
- 208000012902 Nervous system disease Diseases 0.000 claims description 7
- 206010041250 Social phobia Diseases 0.000 claims description 6
- 208000015114 central nervous system disease Diseases 0.000 claims description 6
- 208000019116 sleep disease Diseases 0.000 claims description 6
- 208000008811 Agoraphobia Diseases 0.000 claims description 4
- 208000029197 Amphetamine-Related disease Diseases 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 4
- 208000020706 Autistic disease Diseases 0.000 claims description 4
- 208000022497 Cocaine-Related disease Diseases 0.000 claims description 4
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 4
- 201000006145 cocaine dependence Diseases 0.000 claims description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 4
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 4
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 4
- 208000019906 panic disease Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 206010012239 Delusion Diseases 0.000 claims description 2
- 208000001836 Firesetting Behavior Diseases 0.000 claims description 2
- 208000010235 Food Addiction Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 208000004547 Hallucinations Diseases 0.000 claims description 2
- 201000001916 Hypochondriasis Diseases 0.000 claims description 2
- 208000030990 Impulse-control disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010034158 Pathological gambling Diseases 0.000 claims description 2
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 2
- 238000013019 agitation Methods 0.000 claims description 2
- 208000014679 binge eating disease Diseases 0.000 claims description 2
- 229960003920 cocaine Drugs 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 229960003638 dopamine Drugs 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 230000005176 gastrointestinal motility Effects 0.000 claims description 2
- 230000003370 grooming effect Effects 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 208000020016 psychiatric disease Diseases 0.000 claims description 2
- 201000004645 pyromania Diseases 0.000 claims description 2
- 229940076279 serotonin Drugs 0.000 claims description 2
- 230000000697 serotonin reuptake Effects 0.000 claims description 2
- 208000012201 sexual and gender identity disease Diseases 0.000 claims description 2
- 208000015891 sexual disease Diseases 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 201000009032 substance abuse Diseases 0.000 claims description 2
- 231100000736 substance abuse Toxicity 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783685P | 2018-12-21 | 2018-12-21 | |
| US62/783,685 | 2018-12-21 | ||
| PCT/US2019/067902 WO2020132474A1 (en) | 2018-12-21 | 2019-12-20 | Organic compound |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022515766A JP2022515766A (ja) | 2022-02-22 |
| JPWO2020132474A5 true JPWO2020132474A5 (enExample) | 2022-12-14 |
| JP7377871B2 JP7377871B2 (ja) | 2023-11-10 |
Family
ID=71102341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535939A Active JP7377871B2 (ja) | 2018-12-21 | 2019-12-20 | 有機化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US12195463B2 (enExample) |
| EP (1) | EP3897643B1 (enExample) |
| JP (1) | JP7377871B2 (enExample) |
| WO (1) | WO2020132474A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3011983A1 (en) | 2016-01-26 | 2017-08-03 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines |
| IL272252B2 (en) | 2017-07-26 | 2024-03-01 | Intra Cellular Therapies Inc | Derivatives of substituted heterocycle fused gamma-carbolines, pharmaceutical compositions comnprising them and their use in treatment |
| MX2020007271A (es) | 2017-09-26 | 2020-08-17 | Intra Cellular Therapies Inc | Sales y cristales novedosos. |
| MX2020009928A (es) | 2018-03-23 | 2021-01-08 | Intra Cellular Therapies Inc | Compuestos organicos. |
| CN113423568A (zh) | 2018-12-17 | 2021-09-21 | 细胞内治疗公司 | 有机化合物 |
| AU2019403149B2 (en) | 2018-12-17 | 2025-04-03 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| KR102901722B1 (ko) | 2018-12-17 | 2025-12-17 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로사이클 융합 감마-카르볼린 합성 |
| US12331052B2 (en) | 2018-12-21 | 2025-06-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN117425652A (zh) * | 2021-06-07 | 2024-01-19 | 细胞内治疗公司 | 新盐和晶体 |
| EP4493560A4 (en) * | 2022-03-14 | 2026-03-18 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| WO2025257090A1 (en) | 2024-06-10 | 2025-12-18 | Interquim, S.A. | Process for the preparation of synthesis intermediates of lumateperone and lumateperone analogues |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4238607A (en) | 1972-06-19 | 1980-12-09 | Endo Laboratories Inc. | Pyridopyrrolo benzheterocycles |
| IE41352B1 (en) | 1974-04-01 | 1979-12-19 | Pfizer | 5-aryl-1,2,3,4-tetrahydro- -carbolines |
| AU6541786A (en) | 1985-10-09 | 1987-05-05 | Desitin Arzneimittel Gmbh | Process for producing an administration or dosage form of drugs, reagents or other active ingredients |
| HU208484B (en) | 1988-08-17 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia |
| US5114976A (en) | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
| MXPA01012914A (es) | 1999-06-15 | 2004-04-21 | Bristol Myers Squibb Co | Gama-carbolinas fundidas de heterociclo substituido. |
| US7071186B2 (en) | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
| US6849619B2 (en) | 2000-12-20 | 2005-02-01 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
| MXPA03005438A (es) | 2000-12-20 | 2004-05-05 | Bristol Myers Squibb Co | Pirioindoles substituidos como agonistas y antagonistas de serotonina. |
| JP2005526691A (ja) | 2001-08-08 | 2005-09-08 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 治療剤１Ｈ−ピリド［４，３−ｂ］インドール |
| US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| AU2005286943A1 (en) | 2004-09-20 | 2006-03-30 | Mount Sinai School Of Medicine | Use of memantine (NAMENDA) to treat autism, compulsivity, and impulsivity |
| WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| CN101796051B (zh) | 2007-03-12 | 2013-11-06 | 细胞内治疗公司 | 与取代的杂环稠合的γ-咔啉的合成 |
| CN101842010A (zh) | 2007-08-01 | 2010-09-22 | 梅迪维新神经学公司 | 使用抗精神病的组合治疗产品来治疗精神分裂症的方法和组合物 |
| EP2262502A4 (en) | 2008-02-05 | 2011-12-28 | Clera Inc | Compositions and methods for alleviating depression or improving cognition |
| WO2009114181A2 (en) | 2008-03-12 | 2009-09-17 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines solid |
| USRE48839E1 (en) | 2008-05-27 | 2021-12-07 | Intra-Cellular Therapies, Inc | Methods and compositions for sleep disorders and other disorders |
| EP2560676B8 (en) | 2010-04-22 | 2016-10-12 | Intra-Cellular Therapies, Inc. | Organic compounds |
| TWI582092B (zh) | 2010-07-28 | 2017-05-11 | 歌林達股份有限公司 | 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物 |
| EP2836211B1 (en) | 2012-04-14 | 2019-03-20 | Intra-Cellular Therapies, Inc. | Treatment of PTSD and impulse control disorders |
| US10118926B2 (en) | 2012-09-14 | 2018-11-06 | AbbVie Deutschland GmbH & Co. KG | Tricyclic quinoline and quinoxaline derivatives |
| PT2968320T (pt) | 2013-03-15 | 2021-01-28 | Intra Cellular Therapies Inc | Compostos orgânicos |
| IL321987A (en) | 2013-12-03 | 2025-09-01 | Intra Cellular Therapies Inc | A long-acting injectable preparation containing polymeric microspheres of modified compressed gamma-carboline heterocyclic compounds or a sustained-release pharmaceutical preparation containing these compounds for use in the treatment of bipolar I and/or bipolar II disorders |
| CN106456638A (zh) | 2014-04-04 | 2017-02-22 | 细胞内治疗公司 | 有机化合物 |
| WO2015154025A1 (en) | 2014-04-04 | 2015-10-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| KR20240039186A (ko) | 2015-06-03 | 2024-03-26 | 트리아스텍 인코포레이티드 | 제형 및 이의 용도 |
| CA3011983A1 (en) * | 2016-01-26 | 2017-08-03 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines |
| EP3407889B1 (en) | 2016-03-25 | 2021-05-19 | Intra-Cellular Therapies, Inc. | Organic compounds and their use in treating or preventing central nervous system disorders |
| WO2017165755A1 (en) | 2016-03-25 | 2017-09-28 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP6997718B2 (ja) | 2016-03-28 | 2022-01-18 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規共結晶 |
| JP2019513143A (ja) | 2016-03-28 | 2019-05-23 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規塩類および結晶 |
| WO2018126143A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2018175969A1 (en) | 2017-03-24 | 2018-09-27 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
| IL272252B2 (en) | 2017-07-26 | 2024-03-01 | Intra Cellular Therapies Inc | Derivatives of substituted heterocycle fused gamma-carbolines, pharmaceutical compositions comnprising them and their use in treatment |
| KR102899502B1 (ko) | 2017-07-26 | 2025-12-11 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| MX2020009928A (es) | 2018-03-23 | 2021-01-08 | Intra Cellular Therapies Inc | Compuestos organicos. |
| WO2019237037A1 (en) | 2018-06-08 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Novel methods |
| US20220160704A2 (en) | 2018-08-08 | 2022-05-26 | Torralva Medical Therapeutics Llc | Compositions for opiate and opioid prevention and reversal, and methods of their use |
| CN113423568A (zh) | 2018-12-17 | 2021-09-21 | 细胞内治疗公司 | 有机化合物 |
| US12331052B2 (en) | 2018-12-21 | 2025-06-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP3946345A4 (en) | 2019-04-04 | 2023-01-04 | Intra-Cellular Therapies, Inc. | METHODS OF TREATMENT OF NEUROPATHIC PAIN |
| CA3139168A1 (en) | 2019-05-07 | 2020-11-12 | Nirsum Laboratories, Inc. | Opioid receptor antagonist prodrugs |
-
2019
- 2019-12-20 US US17/416,997 patent/US12195463B2/en active Active
- 2019-12-20 JP JP2021535939A patent/JP7377871B2/ja active Active
- 2019-12-20 WO PCT/US2019/067902 patent/WO2020132474A1/en not_active Ceased
- 2019-12-20 EP EP19900079.5A patent/EP3897643B1/en active Active